Abstract A polymorphism at codon 655 (ATC/isoleucine to GTC/valine [Ile 655 Val], rs1801200) in the transmembrane domain-coding region of human ERBB2 gene has been previously evaluated for its association with breast cancer risk with mixed results. We evaluated this polymorphism in association with breast cancer in a group of women who participated in a large-scale, population-based, case-control study of breast cancer in Shanghai, China, followed by an in vitro analysis of the function of this polymorphism. Genomic DNA from 3,012 patients with breast cancer and 3,004 healthy controls was examined for the Ile 
Introduction
ErbB2 (HER2/Neu), a member of the ErbB family of transmembrane receptor tyrosine kinases which include the epidermal growth factor receptor (EGFR, ErbB1), ErbB3 (HER3), and ErbB4 (HER4), plays an important role in mammary gland development, transformation, and cancer progression [1, 2] . Binding of their cognate ligands to the ectodomain of receptors results in the formation of receptor homodimers or heterodimers and activates receptors by phosphorylation of specific tyrosine residues within the cytoplasmic domain. These phosphorylated residues serve as docking sites for a range of signal molecules and lead to the activation of cascades of intracellular signaling pathways including the mitogen-activated protein kinase (MAPK) and phosphatidylinositol-3 kinase (PI3K) pathways [3] . ErbB2 has no activating ligand, thus it can only signal as a heterodimer activated by the other ErbB receptor ligands. Despite this apparent limitation, ErbB2 is the favorite receptor for heterodimerization and offers more potent mitogenic and transforming signals within the ErbB receptor network [4] . ErbB2 is overexpressed in approximately 20-30% breast cancer, primarily due to gene amplification and this feature correlates with poor patient prognosis [5] [6] [7] . Mutation in the juxta-transmembrane region (Val 664 Glu) of Neu (the rat homologue of human ErbB2) results in the development of focal mammary tumors [8] [9] [10] . Although this mutation has not been identified in humans [11, 12] , a common genetic variant in the nearby transmembrane region at codon 655 was identified in the human ERBB2 gene. This polymorphism encodes either isoleucine (Ile; ATC) or valine (Val; GTC) [13] . Several epidemiologic studies have been conducted during the past several years to investigate ERBB2 Ile 655- Val polymorphism in relation to breast cancer risk [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] . However, the findings from these studies have been inconsistent, and no convincing conclusions have been drawn. Herein, we report the results from a combination of an in vitro functional study and a large population-based case-control study to evaluate the role of ERBB2 Ile 655 Val genetic polymorphisms in breast cancer risk, as well as the modifying effects of this polymorphism on the association between estrogen exposure and breast cancer risk.
Materials and methods

Study subjects
Biological samples and relevant clinical and survey data were collected from more than 3,000 breast cancer patients and controls who participated in the Shanghai Breast Cancer Study (SBCS). The SBCS is a two-phase population-based case-control study; details of study design have previously been described elsewhere [25] . Briefly, in the phase I study, 1,602 eligible cases (women between 25 and 64 years of age with newly diagnosed breast cancer) were identified between 1996 and 1998 through a rapid caseascertainment system supplemented by the Shanghai Cancer Registry. Of these, 1,459 (91.1%) participated in the study. Controls were frequency-matched to cases by age (5-year interval) and randomly selected from the Shanghai Resident Registry. Of 1,724 eligible controls, 1,556 (90.3%) were interviewed. The phase II cases and controls were recruited between April 2002 and February 2005 using a protocol similar to that describe above. The age range of the second stage of the study was between 20 and 70 years. A total of 1,999 cases and 1,918 controls were recruited, with participation rates of 83.7% for cases and 70.4% for controls. The study protocol was approved by committees of relevant institutes for the use of human subjects in research.
All participating cases and controls completed a face-toface interview. A structured questionnaire was used to elicit detailed information on demographic factors, menstrual and reproductive history, medication use, dietary habits, prior disease history, physical activity, tobacco and alcohol use, weight, and family history of cancer. All participants were measured for their current weight, height, and circumference of the waist and hips. All measurements were taken twice by trained interviewers using a standard protocol. A third measurement was taken if the difference from the two measurements exceeded the tolerance level. Medical charts were reviewed to obtain information on cancer diagnosis, tumor-node-metastasis (TNM) stage, estrogen receptor (ER) and progesterone receptor (PR) status, and cancer treatments. Pathologic slides for all cases were reviewed independently by two senior pathologists to confirm cancer diagnosis. Many quality control procedures were implemented in the study to assure the high quality of data collection.
In addition to the in-person interviews, a blood sample or exfoliated buccal cell sample was obtained from the majority of study subjects. Blood samples were collected in Vacutainer tubes containing EDTA or heparin, and buccal cell samples were collected by a modified mouth washing method. All samples were processed on the same day, typically within 6 h, at the Shanghai Cancer Institute and stored at À70°C until relevant bioassays could be conducted. In the initial stage of the study during 1996 and 1998, 1,193 (82%) cases and 1,310 (84%) controls donated a blood sample. In the second stage of the study during 2002 and 2005, virtually all cases (96.5%) and controls (94.3%) provided a blood sample or a buccal cell sample. These subjects were included in the current study.
Genomic DNA was extracted from buffy coats or buccal cells using a Puregene (Gentra Systems, Minneapolis, MN) or Qiagen (Valencia, CA) DNA purification kit following the manufacturer's protocol. The allelic discrimination of the ERBB2 gene Ile
655
Val polymorphism was assessed with the ABI PRISM 7900 Sequence Detection Systems (Applied Biosystems, Foster City, CA) using the TaqMan assay (assay ID: C_7452451_1_). The final volume for each reaction was 5 ll, consisting of 2.5 ll TaqMan Universal PCR Master Mix, 0.25 ll primers/TaqMan probes mix, and 5 ng genomic DNA. The PCR profile consisted of an initial denaturation step at 95°C for 10 min and 40 cycles of 92°C for 15 s and 60°C for 1 min. The fluorescence level was measured with the ABI PRISM 7900HT sequence detector (Applied Biosystems). Allele frequencies were determined by ABI SDS software. Genotyping data were obtained from 3,012 cases and 3,004 controls.
The laboratory staff was blind to the identity of the subjects. Quality control samples were included in genotyping assays. Each 384-well plate contained two water, eight CEPH 1347-02 DNA, eight blinded quality control DNA, and eight unblinded quality control DNA samples. The blinded and unblinded quality control samples were taken from the second tube of study samples included in the study. The genotypes of quality control samples and study samples were in 98% agreement. In addition, 45 DNA samples of the Chinese participants used in HapMap and 24 DNA samples used in Perlegen were genotyped as an additional quality control. The genotypes of the same samples generated from our study were compared to data downloaded from HapMap (http://www.hapmap.org) and/ or Perlegen (http://genome.perlegen.com). The concordance rates between the data generated in our lab and the data from the above database was 100%.
Cell lines, plasmids, and viruses MCF10A cells and its derivative cells were grown in DMEM/F12 medium containing 5% horse serum, EGF (20 ng/ml), Hydrocortizone (0.5 lg/ml), Cholera toxin (100 ng/ml), insulin (10 lg/ml), and Pen/Strep as described elsewhere [26] . Phoenix-Ampho cells were grown in Dulbecco's modified Eagle's medium (DMEM; Cellgro) containing 10% FBS (Hyclone) in a humidified 5% CO2 incubator at 37°C. 
Immunoblot analysis
About 24 h after plating, the stably transduced MCF10A cells were serum starved for 24 h in serum-free DMEM/ F12 medium. Some cells were treated with 10 ng/ml EGF for 45 min before being lysed. Cells were washed twice with ice-cold PBS and lysed on ice in NP-40 lysis buffer (20 mM Tris [pH 7.4], 150 mM NaCl, 1% Nonidet P-40, 0.1 mM EDTA, plus protease and phosphatase inhibitors). After sonication for 10 s and centrifugation (14,000 rpm), the protein concentration in supernatants was measured using the BCA protein assay reagent (Pierce, IL). About 25 lg of total cell protein were separated by 10% SDS-PAGE and transferred onto nitrocellulose membranes (BioRad, Hercules, CA). Primary antibodies included P-HER2Y1248, ErbB2, Erk1/2, AKT, and phosphorylated AKT (Ser 473 ) (Cell Signaling Technology, Beverly, MA) along with P-MAPK (Promega, WI) and b-actin (Sigma, St. Louis, MO). Immunoreactive bands were detected by enhanced chemiluminescence after incubation with horseradish peroxidase-conjugated secondary antibodies (Promega).
Soft agarose colony-forming assay
Base layers consisting of a growth medium containing 0.8% low-melting point agarose (Gibco, Carlsbad, CA) and 10 mM HEPES (pH 7.5) were poured onto 6-well plates and allowed to solidify. Cells (3 · 10 4 per well) were plated in triplicate in top layers consisting of a growth medium containing 0.4% agarose and 5 mM HEPES. Colonies were photographed after 13-18 days.
Statistical analysis
Statistical methods for analysis of case-control data were utilized with SAS (version 9.1; SAS Institute, Cary, NC). Chi-square test or t-test were used to compare demographic factors and major risk factors between cases and controls. Unconditional logistic regression analysis was used to estimate odds ratios (ORs) and corresponding 95% confidence intervals (CIs) for measuring the strength of the association between ERBB2 polymorphisms and the breast cancer risk. Trend tests for dose-response relationships between breast cancer risk and the number of the Val allele were performed by treating an ordinal-score variable (with a value of 0, 1, or 2 for number of Val alleles) as a continuous variable in logistic regression. All statistical tests were two-sided.
Results
Ile 655 Val polymorphism of ERBB2 was not associated with breast cancer risk
The distributions of demographic characteristics and major risk factors for breast cancer are shown in Table 1 for case patients and control subjects. Breast cancer cases and controls were comparable in age due to the frequencymatch study design by age. There were significant differences between cases and controls in education and most of the known risk factors for breast cancer [27] . The associations of these risk factors with breast cancer were similar in the two phases of study, although women in the phase II study were slightly older and slightly better educated than those recruited in the phase I study.
Genotype frequencies among cases and controls are listed in Table 2 . The distribution of the ERBB2 genotype in cases and controls was consistent with Hardy-Weinberg equilibrium. Among subjects recruited in phase I, women with the Val/Val genotype had a slightly elevated risk of breast cancer (OR = 1.5; 95% CI = 0.8-2.7), and the association was seen only in pre-menopausal women (OR = 2.3; 95% CI = 1.0-5.0). This positive association was not replicated in the phase II study. Overall, this polymorphism was not related to the risk of breast cancer in combined or stratified analysis. Val 655 (VV). The cells were also transduced with a previously characterized oncogenic ErbB2 Val 659 Glu (VE), a point mutation in the transmembrance domain resulting in the substitution of valine (V) with glutamic acid (E) at residue 659 [28] . After selection, transgene expression and its downstream effectors, AKT and Mapk (Erk1/2), were detected by immunoblot under serum starvation and EGF stimulation condition, respectively. Under both conditions, the results showed that transduced MCF10A cells expressed an equal level of ErbB2 (II), ErbB2 (VV), ErbB2 (IV), and a lower level of ErbB2 (VE) (Fig. 1A ). MCF10A cells with ErbB2 Val 659 Glu exhibited a higher level of phosphorylated ErbB2 and elevated phosphorylated AKT (only under serum starvation condition) and Erk1/2, two important ErbB2 downstream targets which regulate survival and proliferation signaling. The cells containing other ErbB2 variant exhibited equal levels of a tyrosine phosphorylated ErbB2, phosphorylated AKT, and Erk1/2 ( Fig. 1A and B) . These results indicate that Ile 655 Val substitution in ErbB2 did not alter ErbB2 and its downstream signal molecules activity.
We also examined whether ErbB2 Ile 655 Val substitution results in enhanced transformation ability. The anchorageindependent colony-forming assays were carried out with MCF10A mammary epithelial cells transduced with ERBB2 variants. The transforming activity of the protein encoded by ErbB2 IV was compared with wild type ErbB2 II, ErbB2 VV, and previously characterized transforming ErbB2 VE. The results showed cells expressing ErbB2 II, Glu (VE), were subjected to immunobloting. Levels of total ErbB2 and phosphorylated ErbB2 (P-ErbB2), Akt and phosphorylated Akt (P-Akt), Erk1/2 and phosphorylated Erk1/2 (P-ERK) were analyzed by immunoblotting. Note cells transduced by ErbB2 II, IV, and VV expressed equal levels of ErbB2 protein, whereas the ErbB2 VE level was lower. (B) Relative expression or activity to wild type ErbB2 II. The proteins were quantified by BioQuant NOVA Prime imaging analysis software (BioQuant, Nashville, TN). Normalized phosphorylation of ErbB2, AKT and Erk1/2 were cumulative results of three independent experiments. Tublin serves as loading control. * P < 0.05 compared with other ErbB2 variants ErbB2 IV and ErbB2 VV failed to transform MCF10A mammary epithelial cells, whereas expression of oncogenic ErbB2 VE resulted in induction of foci (Fig. 2) . These results indicate that Ile 655 Val substitution in ErbB2 does not alter ErbB2 transforming activity.
Discussion
Over the past few years, several epidemiologic studies including our study in Shanghai, China, have investigated the association of Ile 655 Val polymorphism in ERBB2 gene with breast cancer risk [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] . The results, however, were inconsistent. In the present study, we conducted a twophase case-control study and in vitro experiments to examine the function of Ile 655 Val substitution in ErbB2. Although a positive association was suggested with the Val allele in the initial set of subjects, particularly for those with an early-onset of breast cancer, this association was not replicated in the second set of subjects. Val substitution in ErbB2 could result in its activity change and influence breast cancer risk. To this aim, we first carried out in vitro biochemical analyses to examine whether Ile 655 Val substitution in ErbB2 had any effects on ERBB2 expression and its activity through examining ErbB2 autophosphorylation (at Tyr1248) and colony-forming assays. Our results showed that ErbB2 carrying Ile 655 Val substitution (IV) is expressed at the same level as the wild type ErbB2 (II) and ErbB2 (VV) in MCF10A mammary epithelial cells. They were also phosphorylated at the same degree. The two major downstream signaling molecules AKT and MAPK, which regulate cell survival and proliferation, were also not affected. In contrast, the oncogenic ErbB2 VE showed higher autophosphorylation and higher phosphorylated AKT (under starvation condition only) and MAPK, which resulted in transformation of MCF10A mammary epithelial cells. Those results are not surprising since (1) both isoleucine and valine have similar aliphatic side chains and substituting one with another probably will not dramatically change the characteristics of underlying protein; and (2) only substituted glutamic acid (E) or glutamine (Q) residues at amino acid positions 664 activate the neu gene, not positions 663 or 665. Even substitution of valine with histidine (H) or lysine (K) at 664 was insufficient to activate the neu, while substitution of valine with aspartic acid (D) only resulted in a small number of foci [29] . We then evaluated whether the Ile 655 Val substitution altered its oncogenic ability. Results from our in vitro colony forming assays clearly indicated that Ile 655 Val substitution in ErbB2 does not have any effect on clonogenicity compared to the oncogenic ErbB2 VE controls.
The current study has several strengths compared to our previous study and other studies. Most importantly, a twophase design was used to reduce type I errors, and the sample sizes in both stages were large so that type II errors were reduced. The population-based case-control study design and high participation rate minimized selection bias. Extensive information on anthropometrics and lifestyle factors were collected in this study for adjusting for confounding factors. Additionally, Chinese women living in Shanghai are relatively homogeneous in ethnic background; over 98% are classified into a single ethnic group (Han Chinese). Therefore, the potential confounding effect by ethnicity is not a major concern for our study. Furthermore, our in vitro biological functional study further confirms the null association results observed in the case-control study.
Taken together, the results from this study do not support a potential role of the ERBB2 Ile 655 Val polymorphism in the etiology of breast cancer that was suggested in several previous studies [17] [18] [19] [20] [21] 23 ], including our own study [14] conducted in a smaller set of subjects, in which the possibility for genotyping and type I errors could be a concern. Our study underscores the importance of replication using independent samples to reduce type I errors and in vitro functional studies in the evaluation of low penetrance genetic factors.
